Latest Research And Development News

Complii FinTech Solutions reported an 11.8% increase in customer receipts for Q4 FY25, alongside a 4.3% quarterly rise in annual recurring revenue, underscoring its expanding footprint in capital raising and compliance software.

Imugene Limited has launched a $37.5 million equity raising through a Placement and Share Purchase Plan, offering new shares and options to fund its pivotal azer-cel clinical program. The raise includes attaching and piggyback options, subject to shareholder approval, aiming to bolster the company’s immuno-oncology pipeline.

Lumos Diagnostics has inked a landmark six-year exclusive distribution agreement with PHASE Scientific for its FebriDx® rapid diagnostic test in the US, potentially unlocking nearly half a billion Australian dollars in revenue contingent on FDA approval.

Phoslock Environmental Technologies reported a $474,000 cashflow deficit in Q2 2025, with sales impacted by deferred European projects and ongoing US tariff uncertainties. Factory refurbishment delays push production restart to early 2026.

Great Dirt Resources has secured a significant exploration licence in the Pilbara lithium province and bolstered its finances with a $335,000 R&D tax rebate, setting the stage for accelerated exploration activities.

Archer Materials advances its quantum computing and medical diagnostics technologies, extending key partnerships and forming a new advisory board while maintaining a strong cash position to fuel development.

InteliCare Holdings has raised $1 million through a structured financing deal to extend its cash runway and scale its AI-driven healthcare platform across aged care and disability sectors.

ClearVue Technologies and LandGlass subsidiary LandVac have entered a strategic partnership to co-develop and commercialize advanced solar vacuum insulated glazing products, aiming to revolutionize energy-efficient building materials worldwide.

Island Pharmaceuticals has accelerated its acquisition of the Galidesivir antiviral program from BioCryst Pharmaceuticals, adding a clinically advanced asset with significant US government backing and a promising regulatory pathway.

Sparc Technologies progresses its pioneering green hydrogen pilot plant and graphene-based coatings, backed by a significant government grant and a successful capital raise.

Orthocell Limited has reported a record FY2025 revenue of A$9.19 million, driven by strong sales of its nerve repair product Remplir™ in Australia and a promising US market launch following FDA clearance.

DroneShield Limited has landed a significant $11.7 million follow-on research contract from a Five Eyes Department of Defence customer, marking its fourth award from this strategic alliance.